A screening test for the presence of Epstein-Barr virus DNA to find early stage nasopharyngeal cancer.
EBV DNA Quantitation has been found to be useful for the monitoring of treatment response and prognostication of EBV associated malignancies, such as nasopharyngeal cancer (NPC), infectious mononucleosis (IM), lymphoproliferative disease and lymphoma.
This is a blood test monitoring for tumour DNA circulating in the bloodstream – also referred to as a “liquid biopsy”. It tests for the presence of DNA in the blood and is a recognised way to screen for early nasopharyngeal cancer in high-risk individuals without symptoms. Early detection can be lifesaving because it allows early stage treatment. Radiation therapy is often used as treatment for nasopharyngeal cancer.
Nasopharyngeal cancer awareness
In Asia, nasopharyngeal cancer accounts for more than 80% of all cases in the world, with the highest prevalence in Singapore and Malaysia.
Asians aged 40 and above
Healthy individuals with family history of NPC, prolonged exposure to air pollutants and salted fish consumption
Patients diagnosed with NPC and undergoing treatment
When to consider screening?
If you are in the risk group – Asians aged over 40
If you have a family member who has been diagnosed with nose cancer
If you are experiencing nose bleeds, painless neck lumps, hearing loss, facial pain / numbness and blurred or double vision